Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-06-13
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of survivin long peptide vaccine and how it works
with the immune system in treating patients with neuroendocrine tumors that have spread to
other parts of the body (metastatic). Tumor cells make proteins that are not usually produced
by normal cells. The body sees these proteins as not belonging and sends white blood cells
called T cells to attack the tumor cells that contain these proteins. By vaccinating with
small pieces of these proteins called peptides, the immune system can be made to kill tumor
cells. Giving survivin long peptide vaccine to patients who have survivin expression in their
tumors may create an immune response in the blood that is directed against neuroendocrine
tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
National Cancer Institute (NCI) NeuroEndocrine Tumor Research Foundation (NETRF)